NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression
Neuronetics, Inc. (NASDAQ: STIM) announced its participation at the American Academy of Child and Adolescent Psychiatry (AACAP) conference in Seattle, WA, from October 14th-19th. The company will present data on the NeuroStar TMS System in an oral presentation at the 'Research Pipeline: New Findings on Therapeutics' session. This presentation will feature the largest study to date evaluating TMS efficacy in adolescents with depression.
Dr. Paul E. Croarkin will present the study, which demonstrates the benefits of TMS treatment for both depressive symptoms and anxiety in adolescents and young adults. The data shows a 78% response rate and 48% remission rate for this population. NeuroStar is the only TMS device FDA-cleared to treat adolescents aged 15 and older as a first-line adjunct treatment for major depressive disorder.
Neuronetics, Inc. (NASDAQ: STIM) ha annunciato la sua partecipazione alla conferenza dell'American Academy of Child and Adolescent Psychiatry (AACAP) a Seattle, WA, dal 14 al 19 ottobre. L'azienda presenterà dati sul NeuroStar TMS System durante una presentazione orale nella sessione 'Research Pipeline: New Findings on Therapeutics'. Questa presentazione presenterà il più grande studio fino ad oggi che valuta l'efficacia della TMS negli adolescenti con depressione.
Il Dr. Paul E. Croarkin presenterà lo studio, che dimostra i benefici del trattamento TMS sia per i sintomi depressivi che per l'ansia negli adolescenti e nei giovani adulti. I dati mostrano un tasso di risposta del 78% e un tasso di remissione del 48% per questa popolazione. NeuroStar è l'unico dispositivo TMS approvato dalla FDA per trattare gli adolescenti di 15 anni e oltre come trattamento di prima linea in aggiunta per il disturbo depressivo maggiore.
Neuronetics, Inc. (NASDAQ: STIM) anunció su participación en la conferencia de la American Academy of Child and Adolescent Psychiatry (AACAP) en Seattle, WA, del 14 al 19 de octubre. La compañía presentará datos sobre el NeuroStar TMS System en una presentación oral en la sesión 'Research Pipeline: New Findings on Therapeutics'. Esta presentación contará con el estudio más grande hasta la fecha que evalúa la eficacia de la TMS en adolescentes con depresión.
El Dr. Paul E. Croarkin presentará el estudio, que demuestra los beneficios del tratamiento TMS tanto para los síntomas depresivos como para la ansiedad en adolescentes y jóvenes adultos. Los datos muestran una tasa de respuesta del 78% y una tasa de remisión del 48% para esta población. NeuroStar es el único dispositivo TMS aprobado por la FDA para tratar a adolescentes de 15 años o más como tratamiento de primera línea complementario para el trastorno depresivo mayor.
Neuronetics, Inc. (NASDAQ: STIM)는 10월 14일부터 19일까지 워싱턴 주 시애틀에서 열리는 아동 및 청소년 정신의학회(AACAP) 컨퍼런스에 참여한다고 발표했습니다. 회사는 'Research Pipeline: New Findings on Therapeutics' 세션에서 NeuroStar TMS System에 대한 데이터를 구두 발표할 예정입니다. 이 발표는 청소년 우울증 치료에서 TMS 효능을 평가한 지금까지의 가장 큰 연구를 포함할 것입니다.
Paul E. Croarkin 박사가 이 연구를 발표하며, 이는 청소년과 젊은 성인에서 TMS 치료의 우울증 증상 및 불안에 대한 이점을 보여줍니다. 데이터는 이 인구에 대해 78%의 반응율과 48%의 평온율을 보여줍니다. NeuroStar는 15세 이상 청소년을 주요 우울 장애에 대한 1차 보조 치료로 치료하기 위해 FDA의 승인을 받은 유일한 TMS 장치입니다.
Neuronetics, Inc. (NASDAQ: STIM) a annoncé sa participation à la conférence de l'American Academy of Child and Adolescent Psychiatry (AACAP) à Seattle, WA, du 14 au 19 octobre. L'entreprise présentera des données sur le NeuroStar TMS System lors d'une présentation orale dans la session 'Research Pipeline: New Findings on Therapeutics'. Cette présentation mettra en avant la plus grande étude à ce jour évaluant l'efficacité de la TMS chez les adolescents souffrant de dépression.
Le Dr Paul E. Croarkin présentera l'étude, qui démontre les avantages du traitement TMS pour les symptômes dépressifs ainsi que pour l'anxiété chez les adolescents et les jeunes adultes. Les données montrent un taux de réponse de 78% et un taux de rémission de 48% pour cette population. NeuroStar est le seul dispositif TMS autorisé par la FDA pour traiter les adolescents de 15 ans et plus en tant que traitement adjuvant de première ligne pour le trouble dépressif majeur.
Neuronetics, Inc. (NASDAQ: STIM) gab bekannt, dass es an der Konferenz der American Academy of Child and Adolescent Psychiatry (AACAP) in Seattle, WA, vom 14. bis 19. Oktober teilnehmen wird. Das Unternehmen wird Daten zum NeuroStar TMS System in einer mündlichen Präsentation in der Sitzung 'Research Pipeline: New Findings on Therapeutics' vorstellen. Diese Präsentation wird die größte Studie bislang zur Beurteilung der TMS-Effektivität bei Jugendlichen mit Depressionen präsentieren.
Dr. Paul E. Croarkin wird die Studie vorstellen, die die Vorteile der TMS-Behandlung sowohl für depressive Symptome als auch für Angstzustände bei Jugendlichen und jungen Erwachsenen demonstriert. Die Daten zeigen eine Reaktionsquote von 78% und eine Remissionsquote von 48% für diese Population. NeuroStar ist das einzige TMS-Gerät, das von der FDA genehmigt wurde, um Jugendliche ab 15 Jahren als Erstlinientherapie neben dem schweren depressiven Störungsbehandlungsansatz zu behandeln.
- NeuroStar TMS System selected for oral presentation at AACAP 2024
- Largest study to date evaluating TMS efficacy in adolescents with depression
- 78% response rate and 48% remission rate for adolescents and young adults with MDD
- NeuroStar is the only TMS device FDA-cleared for adolescents aged 15 and older as first-line adjunct treatment
- None.
Insights
This presentation at AACAP 2024 highlights significant findings on NeuroStar TMS efficacy in treating adolescent depression. The study, featuring the largest sample size to date for this age group, reinforces previous safety and efficacy data. Key points include:
- A
78% response rate and48% remission rate for adolescents with major depressive disorder - NeuroStar is the only FDA-cleared TMS device for first-line adjunct treatment in patients aged 15 and older
- The study also shows benefits in treating anxiety symptoms alongside depression
While these results are promising for Neuronetics (STIM), investors should note that this is a presentation of existing data rather than a new clinical trial or FDA approval. The potential market expansion into younger patients could drive future growth, but the immediate financial impact may be Long-term, this data could support increased adoption of NeuroStar TMS in adolescent treatment protocols, potentially boosting revenue.
Data selected for oral presentation reinforce previous findings on safety and efficacy
MALVERN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today their participation at the American Academy of Child and Adolescent Psychiatry (AACAP) in Seattle, WA, from October 14th-19th, including an oral presentation at the “Research Pipeline: New Findings on Therapeutics” session featuring data generated utilizing the NeuroStar TMS (transcranial magnetic stimulation) System. In addition, NeuroStar will exhibit at booth #416, where demonstrations of the device will be given.
“We are proud to present the largest sample to date of adolescents and young adults with major depressive disorder, highlighting the truly unmatched benefit NeuroStar TMS can provide to this population with limited approved treatment options,” said Cory Anderson, Senior Vice President of Research & Development and Clinical. “As the leading TMS device and the only one FDA-cleared to treat adolescents aged 15 and older as a first-line adjunct treatment, NeuroStar is uniquely positioned to support patients and providers by treating young people with depression.”
The following data were selected for a prestigious oral presentation.
A Naturalistic Study of Transcranial Magnetic Stimulation Treatment in Adolescents and Young Adults with Depression and Anxiety
- Presenter: Dr. Paul E. Croarkin, Professor of Psychiatry, Pediatrics, and Pharmacology, Ervin A. and Margaret C. Mueller Director, Mayo Clinic Children's Research Center, Mayo Clinic College of Medicine and Science.
- Overview: In the oral presentation, Dr. Croarkin will present the largest sample to date of adolescents and young adults treated with TMS for MDD, highlighting the benefits of treatment in both depressive symptoms and anxiety for this population.
- Presentation Date: October 16th at 1:30 PM PT
“These data are robust and reinforce the positive trend adolescent psychiatrists have seen since the FDA-clearance of NeuroStar for adolescents aged 15 and up earlier this year, which is the overwhelmingly positive clinical outcomes for young patients with major depressive disorder,” said Dr. Melissa Fickey of Embracing Life Wellness Center, AACAP member, and board-certified child, adolescent, and adult psychiatrist. “With an impressive
For more information about NeuroStar TMS Therapy, please visit www.neurostar.com.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 6.6 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, visit www.neurostar.com.
Media Contact:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com
_______________
1 NeuroStar TMS results analyzed from 1,169 adolescent patients and a subset with available CGI-S data demonstrated a
FAQ
What is the efficacy of NeuroStar TMS for adolescents with depression according to the AACAP 2024 presentation?
Is NeuroStar TMS FDA-cleared for treating adolescents with depression?
When and where will Neuronetics (STIM) present the NeuroStar TMS data at AACAP 2024?
